Gaviscon 16 Chewable Tablets Strawberry 250 +133.5 mg

WARNINGS
Do not use for prolonged treatments. In adolescents (12-18 years) use only in case of real need '. Renal insufficiency: in case of renal insufficiency, the medicine should be used with caution as the exogenous salt supplement provided by antacids can cause potentially serious electrolyte imbalances. Each 500 mg + 267 mg tablet contains 123 mg (5.3 mmol) of sodium. Each 250 mg +133.5 mg tablet contains 61.5 mg (2.65 mmol) of sodium. Each 10 ml dose of suspension contains 141 mg (6.2 mmol) of sodium. Each 500 mg + 267 mg single-dose sachet of oral powder contains 123 mg (5.3 mmol) of sodium. This should be taken into consideration in cases where a particularly low-salt diet is recommended, for example in some cases of congestive heart failure and renal impairment. Each 500mg + 267mg tablet contains 160mg (1.6mmol) of calcium carbonate. Each 250 mg +133.5 mg tablet contains 80 mg (0.8 mmol) of calcium carbonate. Each 10 ml dose of suspension contains 160 mg (1.6 mmol) of calcium carbonate. Each 500 mg + 267 mg single-dose sachet of oral powder contains 160 mg (1.6 mmol) of calcium carbonate. Care should be taken when treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium-containing kidney stones. The tablets and oral powder contain aspartame, a source of phenylalanine: it should therefore not be taken by patients with phenylketonuria. The suspension contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions. Delayed-type reactions (contact dermatitis) usually occur, rarely immediate reactions with urticaria and bronchospasm. Duration of treatment: If symptoms do not improve after seven days, the clinical picture should be re-evaluated.
PHARMACOTHERAPEUTIC CATEGORY
Peptic antiuclera and gastroesophageal reflux disease (GORD).
STORAGE
Oral suspension and mint flavored oral suspension: do not store above 30 degrees C; store in the original packaging; do not refrigerate. Mint flavored oral suspension in sachets: do not store above 25 degrees C; store in the original packaging; do not refrigerate. Mint-flavored chewable tablets: do not store above 30 degrees C; store in the original packaging. Strawberry-flavored chewable tablets: do not store above 25 degrees C; store in the original packaging. Oral powder: do not store above 25 degrees C; store in the original packaging.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substances or to any of the listed excipients, such as methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) (parabens).
NAME
GAVISCON
EXCIPIENTS
Mint flavor chewable tablets: mannitol (E421), calcium carbonate, magnesium stearate, copovidone, aspartame (E951), acesulfame potassium, macrogol 20,000, mint flavor. Strawberry flavored chewable tablets: xylitol, mannitol (E421), calcium carbonate, macrogol 20,000, strawberry flavor, aspartame (E951), magnesium stearate, red iron oxide. Oral suspension: calcium carbonate, carbomers, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), sodium saccharin, aromafinocchio, sodium hydroxide, erythrosine, purified water. Mint aroma oral suspension: calcium carbonate, carbomers, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), sodium saccharin, flavoring, sodium hydroxide, purified water. Oral powder: calcium carbonate, silicon dioxide, granular anhydrous citric acid, mint flavor, aspartame (E951), macrogol 20000, macrogol 400, passion fruit flavor, acesulfame potassium (E950), xylitol.
SIDE EFFECTS
The following are the undesirable effects of the product, organized according to the MedDRA system organ class. They are divided by frequency (very common (> = 1/10), common (> = 1/100 to <= 1/10), uncommon (> = 1 / 1,000 to <= 1/100), rare (> = 1 / 10,000 to 1 / 1,000), very rare (<= 1 / 10,000)). Disorders of the immune system. Very rare: anaphylactic or anaphylactoid reactions. Hypersensitivity reactions' (such as hives). Respiratory, thoracic and mediastinal disorders. Very rare: respiratory symptoms such as bronchospasm. Gastrointestinal disorders. Very rare: flatulence, nausea. General disorders and administration site conditions. Very rare: edema. The reporting of suspected adverse reactions occurring after the authorization of the drug is important, as it allows continuous monitoring of the benefit / risk ratio of the drug.
PREGNANCY AND BREASTFEEDING
Use in case of real need.
INDICATIONS
Symptomatic treatment of occasional heartburn.
INTERACTIONS
It is advisable to interpose an interval of at least two hours between taking the medicine and that of other drugs, especially tetracyclines, fluoroquinolones, iron salts, thyroid hormones, chloroquine, bisphosphonates and estramustine.
DOSAGE
>> Chewable tablets (strawberry flavor and mint flavor). Adults and adolescents (12-18 years): 1-2 tablets of 500 mg + 267 mg after meals and at bedtime. 2-4 tablets of 250 mg + 133.5 mg after meals and at bedtime. Method of administration: for oral administration. The tablets should be chewed well (they can be broken up and chewed a little at a time). Then you can drink some water. >> Oral suspension. Adults and adolescents (12-18 years): 10-20 ml (second-fourth notch of the measuring cup or 2-4 measuring spoons or 1- 2 single-dose sachets) after meals and at bedtime. Method of administration: for oral administration. Shake the suspension before use. >> Oral powder. Adults and adolescents (12-18 years): 1-2 single-dose sachets after meals and at bedtime. Method of administration: take the drug orally without water. Elderly: it is not necessary to modify the doses for this age group. Patients with renal insufficiency: the reduced ability to eliminate exogenous saline supplement provided by antacids in the urine can affect potentially severe electrolyte imbalances.
ACTIVE PRINCIPLES
Sodium alginate; sodium bicarbonate.